Compare Charles River Laboratories Intl. Inc (CRL) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Microsoft — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Microsoft trades at $386.55 (market cap $2.86T). The key difference: Microsoft is far larger — about 256.7× Charles River Laboratories Intl. Inc's market cap, and Microsoft pays a 0.95% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | MSFT | |
|---|---|---|
Market Cap | $11.14B | $2.86T |
Sector | Health | Technology |
52-Week High | $233.60 | $542.07 |
52-Week Low | $145.57 | $352.83 |
Enterprise Value | $14.00B | $2.84T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Microsoft (MSFT) trades at $390.99, up 1.53% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $4.27, beating expectations, and maintains robust profitability with a 39.34% net income margin. Revenue growth is steady, reaching $281.72B in 2025, supported by AI and cloud initiatives. Analyst consensus is overwhelmingly bullish with an 80.49% buy rating and a $552.81 price target.
Outlook remains positive due to AI leadership and consistent earnings beats, but risks include rising capital expenditures and competitive pressures. The stock offers growth potential with a reasonable P/E of 22.93, though investors should monitor execution on AI investments and macroeconomic headwinds that could impact tech valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
